Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123373312 | 12337331 | 2 | F | 20160315 | 20160808 | 20160505 | 20160817 | EXP | US-ASTRAZENECA-2016SE46905 | ASTRAZENECA | 17957.00 | DY | M | Y | 96.20000 | KG | 20160817 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123373312 | 12337331 | 1 | PS | FARXIGA | DAPAGLIFLOZIN PROPANEDIOL | 1 | Oral | 5850 | MG | Y | U | 202293 | 10 | MG | TABLET | QD | |||
| 123373312 | 12337331 | 2 | SS | PRILOSEC | OMEPRAZOLE MAGNESIUM | 1 | Oral | 0 | 10 | MG | CAPSULE | QD | |||||||
| 123373312 | 12337331 | 3 | C | LANTUS | INSULIN GLARGINE | 1 | Subcutaneous | 40 UNITS, AT BEDTIME | 0 | ||||||||||
| 123373312 | 12337331 | 4 | C | NOVOLOG | INSULIN ASPART | 1 | Subcutaneous | 0 | |||||||||||
| 123373312 | 12337331 | 5 | C | ASPIR | ASPIRIN | 1 | Oral | 0 | 1 | DF | TABLET | QD | |||||||
| 123373312 | 12337331 | 6 | C | ASPIR | ASPIRIN | 1 | Oral | 0 | 81 | MG | TABLET | QD | |||||||
| 123373312 | 12337331 | 7 | C | AVAPRO | IRBESARTAN | 1 | Oral | 0 | 1 | DF | TABLET | QD | |||||||
| 123373312 | 12337331 | 8 | C | CYMBALTA | DULOXETINE HYDROCHLORIDE | 1 | Oral | 0 | 30 | MG | CAPSULE | QD | |||||||
| 123373312 | 12337331 | 9 | C | HUMALOG | INSULIN LISPRO | 1 | Subcutaneous | 100 UNITS/ML PEN SLIDING SCALE | 0 | ||||||||||
| 123373312 | 12337331 | 10 | C | HUMALOG | INSULIN LISPRO | 1 | Subcutaneous | 5-10 UNITS | 0 | ||||||||||
| 123373312 | 12337331 | 11 | C | ZOCOR | SIMVASTATIN | 1 | Oral | 0 | 1 | DF | TABLET | QD | |||||||
| 123373312 | 12337331 | 12 | C | INSULIN GLARGINE | INSULIN GLARGINE | 1 | Subcutaneous | 25 UNIT(S),SUBCUTANEOUS,DAILY WITH BREAKFAST | 0 | ||||||||||
| 123373312 | 12337331 | 13 | C | IRBESARTAN. | IRBESARTAN | 1 | Oral | DAILY | 0 | ||||||||||
| 123373312 | 12337331 | 14 | C | ONDANSETRON | ONDANSETRON | 1 | Oral | 1 TABLET, Q8HR,PRN | 0 | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 123373312 | 12337331 | 1 | Type 2 diabetes mellitus |
| 123373312 | 12337331 | 2 | Gastrooesophageal reflux disease |
| 123373312 | 12337331 | 3 | Diabetes mellitus |
| 123373312 | 12337331 | 9 | Diabetes mellitus |
| 123373312 | 12337331 | 10 | Diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 123373312 | 12337331 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 123373312 | 12337331 | Acute kidney injury | |
| 123373312 | 12337331 | Atelectasis | |
| 123373312 | 12337331 | Diabetes mellitus inadequate control | |
| 123373312 | 12337331 | Diabetic ketoacidosis | |
| 123373312 | 12337331 | Glycosylated haemoglobin increased | |
| 123373312 | 12337331 | Hyperglycaemia | |
| 123373312 | 12337331 | Hyperkalaemia | |
| 123373312 | 12337331 | Hypertension | |
| 123373312 | 12337331 | Hypophosphataemia | |
| 123373312 | 12337331 | Metabolic acidosis | |
| 123373312 | 12337331 | Pulmonary fibrosis | |
| 123373312 | 12337331 | Tachycardia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 123373312 | 12337331 | 1 | 20140809 | 20160315 | 0 |